The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).
 
David S. Hong
No Relationships to Disclose
 
John H. Strickler
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Chengdu Kanghong Biotech; Mereo Biopharma; Natera (Inst); Pfizer; Seagen (Inst); Viatris
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly; Exelixis (Inst); Leap Therapeutics (Inst); Nektar (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Seagen
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - Amgen; Guardant Health
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Rocky Mountain Oncology Society
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst); Navire (Inst); Silicon Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Exelixis (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Navire (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); poseida therapeutics (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Regeneron (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Sapience Therapeutics (Inst); Silicon Therapeutics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute
 
Bob T. Li
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); GRAIL (Inst); Guardant Health (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Karger Publishers - Book royalty; Shanghai Jiao Tong University Press - Book royalty; US62/514,661 (Inst); US62/685,057 (Inst)
Travel, Accommodations, Expenses - Jiangsu Hengrui Medicine; MORE Health
(OPTIONAL) Uncompensated Relationships - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Genentech; Lilly
 
Greg Andrew Durm
Honoraria - AstraZeneca; Curio Science
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
 
Timothy F. Burns
Consulting or Advisory Role - Abbvie/Stemcentrx; Blueprint Medicines; Foundation Medicine; Novartis; Thermo Fisher Scientific
Speakers' Bureau - Amgen
 
Suresh S. Ramalingam
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech/Roche; GlaxoSmithKline; Lilly/ImClone; Merck; Mirati Therapeutics; Takeda
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Sarah B. Goldberg
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genzyme; Regeneron
Research Funding - Amgen (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
Richard C. Frank
No Relationships to Disclose
 
Kristen Marrone
Honoraria - AstraZeneca
Consulting or Advisory Role - Amgen; AstraZeneca; Compugen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
 
Catherine A. Shu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech/Roche
Research Funding - Celgene (Inst); Genentech/Roche (Inst); Janssen (Inst); MedImmune (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
David R. Gandara
Honoraria - AstraZeneca; CBPartners; MJH Life Sciences
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Boehringer Ingelheim; Guardant Health (Inst); Inivata; IO Biotech (Inst); Lilly (Inst); Merck; OncoCyte (Inst); Roche/Genentech
Research Funding - Amgen (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Neelesh Soman
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Haby Adel Henary
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Ramaswamy Govindan
Honoraria - Abbvie; Genentech/Abbvie; Geneplus
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech/Roche; GlaxoSmithKline; Ignyta; Janssen; Jounce Therapeutics; Lilly; Merck Serono; Nektar; Pfizer; Phillips Gilmore Oncology; Roche